Home
About Us
Pipeline
Partnerships
Investors
News & Events
Careers
| S*BIO Vision | Background | S*BIO Management | Board of Directors | Scientific Advisory Board | Corporate Values |
| Clinical Trials | Technologies & Capabilities |
| News & Press Releases | Participation in Events | Publications |
| Join Our Team | Career Opportunities |
 |
 |
|
The best scientist is open to experience and begins with romance - the idea that anything is possible. Ray Bradbury |
|
|
|
2007 Publications Biotechnology Journal 2007; 2(11): 1360 – 1368 Function of the SIRT1 protein deacetylase in cancer Walter Stunkel, Bee Keow Peh, Yong Cheng Tan, Vasantha M. Nayagam, Xukun Wang, Manuel Salto-Tellez, Binhui Ni, Michael Entzeroth and Jeanette Wood Biomedical Chromatography 2007; 21(2): 184 – 189 Development and validation of high-performance liquid chromatography-tandem mass spectrometry assay for 6-(3-benzoyl-ureido)-hexanoic acid hydroxyamide, a novel HDAC inhibitor, in mouse plasma for pharmacokinetic studies Pauline Yeo, Liu Xin, Evelyn Goh, Lee Sun New, Peizi Zeng, Xiaofeng Wu, P. Venkatesh and Ethirajulu Kantharaj Biological and Pharmaceutical Bulletin 2007; 30(5): 1021—1024 In vitro Phase I Cytochrome P450 Metabolism, Permeability and Pharmacokinetics of SB639, a Novel Histone Deacetylase Inhibitor in Preclinical Species P. Venkatesh, Evelyn Goh, Peizi Zeng, Lee Sun New, Liu Xin, Mohammed Khalid Pasha, Kanda Sangthongpitag, Pauline Yeo, and Ethirajulu Kantharaj Blood (ASH Annual Meeting Abstracts) Nov 2007; 110: 4201 Pharmacokinetic and Pharmacodynamic Properties of SB1317, a Potent and Orally Active Multi-Kinase Inhibitor Pauline Yeo, P. Venkatesh, Evelyn Goh, Peizi Zeng, Lee S. New, Changyong Hu, Kanda Sangthongpitag, Anthony D. William, Kee Chuan Goh, Jeanette Wood, and Ethirajulu Kantharaj Blood (ASH Annual Meeting Abstracts) Nov 2007; 110: 1593 SB1317, a Potent and Orally Active FLT3-CDK Inhibitor with High Anti-Tumor Efficacy in Models of Hematological Malignancies Kee Chuan Goh, Wai Chung Ong, Changyong Hu, Ai Leng Liang, Walter Stunkel, Yong Cheng Tan, Kanda Sangthongpitag, Siok Kun Goh, Zahid Q. Bonday, Anthony D. William, Brian W. Dymock, Ethirajulu Kantharaj, and Jeanette M. Wood Blood (ASH Annual Meeting Abstracts) Nov 2007; 110: 538 SB1518: A Potent and Orally Active JAK2 Inhibitor for the Treatment of Myeloproliferative Disorders Kee Chuan Goh, Wai Chung Ong, Changyong Hu, Hannes Hentze, Ai Leng Liang, Walter Stunkel, Yong Cheng Tan, Kanda Sangthongpitag, Siok K. Goh, Shirly Sieh, Zahid Q. Bonday, Anthony D. William, Angeline Lee, Stephanie Blanchard, Te C. Liu, Martin Sattler, James D. Griffin, Brian W. Dymock, Ethirajulu Kantharaj, and Jeanette M. Wood Blood (ASH Annual Meeting Abstracts) Nov 2007; 110: 1603 SB939: A Potent and Orally Active HDAC Inhibitor for the Treatment of Hematological Malignancies Kanda Sangthongpitag, Walter Stunkel, Zahid Q. Bonday, Kee C. Goh, Xukun Wang, Xiaofeng Wu, Changyong Hu, Haishan Wang, Niefang Yu, Eric Sun, Michael Entzeroth, Ethirajulu Kantharaj, Chien-Shing Chen, and Jeanette M. Wood AACR Centennial Conference on Translational Cancer Medicine in Singapore, November 2007 SB939: a potent, orally-active HDAC inhibitor for the treatment of hematological malignancies and solid tumors K. Sangthongpitag, H. Wang, W. Stünkel, Z. Bonday, Y. C. Tan, V. M. Nayagam, S. K. Goh, K.C. Goh, W. Xukun, X. Wu, C. Hu, E. Sun, M. Entzeroth, P. Venkatesh, E. Goh, P. Yeo, C.S. Chen, G. Greicius, S. Pettersson, E. Kantharaj and J. Wood AACR-NCI-EORTC conference on Molecular Targets in San Francisco, October 2007 SB939: a potent and orally active HDAC inhibitor for the treatment of colorectal cancer K. Sangthongpitag, G. Greicius, W. Stunkel, K.P. Koh, Y. C. Tan, V.M. Nayagam, Z. Bonday, M. K. Goh, C. P. Ng, K.C. Goh, X.K. Wang, K.L. Goh, W.C. Ong, X.F Wu, C.Y. Hu, H. H. Khng, S. K. Goh, T. Ng, M. Entzeroth, H.S. Wang, N.F Yu, K. Lee, D.Z. Chen, P.L. Lye, J. Chang, M. Ng, W.P. Deng, M. L. Khoo, T. Lu, C.K. Soh, E.T. Sun, P. Yeo, X. Liu, E. Goh, L.S. New, E. Kantharaj, S. Pettersson and J. Wood 8th International ISSX Meeting in Sendai in Japan, 9–12 October 2007 Development of generic LC-MS-MS cocktail analysis method for the characterization of both cytochrome P450 inhibition and phenotyping properties of new chemical entities (NCEs) using Qtrap 3200 system Pauline Yeo, Evelyn Goh, Lee Sun New, Peizi Zeng, Venkatesh. P, Ethirajulu Kantharaj ACS-EFMC Meeting in Siena, Italy , October 2007 Indazoles as potent and selective aurora kinase inhibitors Stéphanie Blanchard, Zahid Bonday, Kay Lin Goh, Kee Chuan Goh, Angeline Lee, Wai Chung Ong, Anders Poulsen, Eric Sun, Ee Ling Teo, Anthony William Rosenön Meeting 2007: “DMPK and PK/PD from Lead to Product - Recent Developments and Trends in an Expanding Science” in Stockholm, Sweden, 20 – 22 September 2007 Pharmacokinetic-pharmacodynamic (PK-PD) relationship of novel HDAC inhibitors in HCT116 mouse xenograft tumor model Pauline Yeo, Evelyn Goh, Peizi Zeng, Venkatesh. P, Ethirajulu Kantharaj CHI's Fifth Annual Protein Kinase Targets in Boston, June 2007 Indazoles as potent and selective aurora kinase inhibitors Stéphanie Blanchard, Zahid Bonday, Kay Lin Goh, Kee Chuan Goh, Angeline Lee, Wai Chung Ong, Anders Poulsen, Eric Sun, Ee Ling Teo, Anthony William
|
